MG
Morningside Group
Venture CapitalActiveMorningside Group is a private investment group founded in 1986 by the Chan family of Hong Kong.
158
Investments
8
Exits
$3B
AUM
5.1%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Morningside Group.
Investment Thesis & Strategy
Morningside Group invests in various stages of biotech, e-commerce, and fintech companies. They look for promising companies with strong potential for growth.
Investment Activity
Deals per year over the last 8 years
1
20110
20121
20131
20142
20153
20163
20171
2018Portfolio Companies
Selected investments from their portfolio of 158 companies
B
BioNTech
Biotech · Growth, 2018
A
Adagene
Biotech · Growth, 2017
T
Terns Pharma
Biotech · Growth, 2017
D
Denovo Biopharma
Biotech · Growth, 2017
X
XtalPi
AI/ML · Series B, 2016
H
Harbour BioMed
Biotech · Growth, 2016
C
CStone Pharmaceuticals
Biotech · Growth, 2016
I
Insilico Medicine
AI/ML · Growth, 2015
I
I-MAB
Biotech · Growth, 2015
L
Legend Biotech
Biotech · Growth, 2014
Z
Zai Lab
Biotech · Growth, 2013
B
BeiGene
Biotech · Growth, 2011
Notable Exits
CompanyTypeYearValue / Acquirer
XtalPiAcquisition2024—
Gan & Lee PharmaceuticalsIPO2021—
Harbour BioMedIPO2020—
Innovent BiologicsIPO2018$3.3B
WuXi AppTecIPO2018$8.8B
Zai LabIPO2017$150M
Celltrion HealthcareIPO2017—
BeiGeneIPO2016$750M
Frequently Asked Questions
Morningside Group focuses on Series A, Series B, Series C+ stage investments.